Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11518974 | 0.94 | SYK (0.57) | MAPTKMT2AMEN1ALDH1A1SYK | |
| SCHEMBL11191264 | 0.88 | MTNR1B (0.52) | MAPTKMT2AMEN1SYKPTK6 | |
| SCHEMBL11667711 | 0.87 | KMT2A (0.47) | MAPTKMT2AMEN1ALDH1A1AR | |
| SCHEMBL27587753 | 0.86 | CYP3A4 (0.59) | MAPTKMT2AMEN1ALDH1A1SYK | |
| SCHEMBL9502179 | 0.84 | SYK (0.47) | KMT2AMEN1SYKPTK6TP53 | |
| SCHEMBL3440767 | 0.82 | MAPT (0.63) | MAPTKMT2AMEN1ALDH1A1HSD17B10 | |
| SCHEMBL9479637 | 0.82 | MAPT (0.63) | MAPTKMT2AMEN1ALDH1A1HSD17B10 | |
| SCHEMBL8962118 | 0.82 | TSHR (0.58) | LTA4HNR1H4TSHR | |
| SCHEMBL2089601 | 0.81 | MAPT (0.54) | MAPTKMT2AMEN1ALDH1A1AR | |
| SCHEMBL27339343 | 0.81 | KMT2A (0.61) | MAPTKMT2AMEN1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117089943-A | Single-walled carbon nanotube reinforced heterocyclic aramid fiber and preparation method thereof | 北京石墨烯研究院 | 2023-11-21 | — | — | CN | claimed |
| CN-117089943-A | Single-walled carbon nanotube reinforced heterocyclic aramid fiber and preparation method thereof | 北京石墨烯研究院 | 2023-11-21 | — | — | CN | disclosed |
| US-20200407658-A1 | ALKYLATED ALKOXYDIARYLAMINE ANTIOXIDANTS | LANXESS SOLUTIONS US INC. (US) | 2020-12-31 | — | — | US | disclosed |
| US-10808197-B2 | Alkylated alkoxydiarylamine antioxidants | LANXESS SOLUTIONS US INC. (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2018057365-A1 | ALKYLATED ALKOXYDIARYLAMINE ANTIOXIDANTS | LANXESS SOLUTIONS US INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20180079984-A1 | ALKYLATED ALKOXYDIARYLAMINE ANTIOXIDANTS | LANXESS CORPORATION | 2018-03-22 | — | — | US | disclosed |
| EP-2585216-A1 | COMPLEXES | Johnson Matthey PLC (GB) | 2013-05-01 | — | — | EP | disclosed |
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| WO-2011161451-A1 | COMPLEXES | JOHNSON MATTHEY PLC (GB) | 2011-12-29 | — | — | WO | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-6218388-B1 | THERAPY OF PROTEIN TYROSINE KINASE MEDIATED CANCER, ATHEROSCLEROSIS, RESTENOSIS, AND PSORIASIS BY ADMINISTERING BENZIMIDAZOLE DERIVATIVE | WARNER-LAMBERT COMPANY | 2001-04-17 | — | — | US | disclosed |
| US-5990146-A | TREATING PROTEIN TYROSINE KINASE MEDIATED CANCER; ANTICARCINOGENIC AGENTS; ATHEROSCLEROSIS; RESTENOSIS; PSORIASIS; ANTIPROLIFERATIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | MAPT 4511/4885KMT2A 568/4885MEN1 3118/4885 |
| US-10808197-B2 | Alkylated alkoxydiarylamine antioxidants | GPX4, CAT, SOD1 | MAPT 2803/4885KMT2A 1818/4885MEN1 4755/4885 |
| US-20200407658-A1 | ALKYLATED ALKOXYDIARYLAMINE ANTIOXIDANTS | GPX4, CAT, SOD1 | MAPT 2803/4885KMT2A 1818/4885MEN1 4755/4885 |
| US-20180079984-A1 | ALKYLATED ALKOXYDIARYLAMINE ANTIOXIDANTS | GPX4, CAT, SOD1 | MAPT 2803/4885KMT2A 1818/4885MEN1 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.